The annual general meeting of aXichem AB (publ) was held on 19 June 2024. The annual general meeting made the following main resolutions:
to determine the income statement, the balance sheet, the consolidated income statement and the consolidated balance sheet and that the company's results would be balanced in a new account;
to grant discharge of liability for the board members and the managing director;
that in accordance with the nomination committee's proposal, the board members shall be remunerated with three base price amounts each and the chairman of the board with six base price amounts;
in accordance with the nomination committee's proposal, to re-elect Jan Gustavsson, Christian Månsson, Jørn H. Berthelsen, Torsten Helsing and Edward van den Elsen as board members, and to elect Michael Engström as new board member. It was also decided to re-elect Jan Gustavsson as chairman of the board and Mazars AB as auditor. Furthermore, Gunilla Savring, who has declined re-election, was thanked for significant contributions to the development of aXichem during the ten years she has worked in the board of directors;
that the nomination committee before the 2025 annual general meeting shall consist of Anders Månsson (LMK Companies) and Torsten Helsing (Manakin LTD) and that the nomination committee shall have the option to decide to appoint a third member to the nomination committee, as a representative of the company's other shareholders. Such possible third member must be appointed by the chairman of the board; and
to authorize the board to, at the latest until the time of the next annual general meeting and on one or more occasions and with or without preferential rights for the shareholders, decide on the issue of new shares, convertibles and/or warrants, however, that such issue must not result in the company's share capital exceeding the company's maximum permitted share capital according to the articles of association.
The information was submitted, through the agency of the contact person, for publication on June 19, 2024, at 12:00 CEST.
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified Adviser for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com.
